Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 2, 1999

View Archived Issues

Company Profile: Intellivax

Company Profile: Artemis

Ortec applies for FDA clearance for Composite Cultured Skin

Schering in-licenses human antibody for gastric cancer

diaDexus and Biosite Diagnostics to collaborate on cardiovascular diagnostic marker discovery

Xoma plans to submit BLA for meningococcemia therapy

FDA finds LeukoScan filing deficient

AxyS achieves milestone in Rhone-Poulenc Rorer collaboration

Lilly presents modified glycopeptides with antibacterial activity

New 5-HT4 ligands from Kyowa Hakko useful for GI motility disorders

CNS-active benzimidazoles and benzothiazoles codeveloped at Taisho/Sagami

V1A/AT1 receptor antagonist combinations for cardiovascular disorders

Fused thiophenes from Ono inhibit IL-6 and/or IL-12 production

Kyowa Hakko prepares antiproliferative agents that interact with the PDGF receptor

ASTMH news: PS-22, a new antimalarial prodrug, tested for toxicity

Phase I/II results support the efficacy of ABX-IL-8 in psoriasis

Bayer's CMV product advances to phase II

Results presented at ASTMH demonstrate safety and efficacy of tafenoquine in malaria

Boston Life Sciences achieves axonal regeneration with second native growth factor

High-affinity polyamine-site NMDA receptor antagonists designed by German researchers

Studies using new transgenic rat model illustrate role of CETP in atherosclerosis

Potent, selective, orally active subtype-selective NMDA antagonists with potential in PD

FDA approves new epilepsy treatment

AR-R18565: new neuroprotective agent acts selectively on N-type calcium channels

Millennium and LeukoSite merger receives early Hart-Scott-Rodino clearance

6-Nitroquinazolines with dual TNF-alpha production/T-cell proliferation-suppressive effects

First murine (and human) CCR1 receptor antagonist reported by Banyu at Japanese meeting

Insmed to acquire Celtrix

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...